1. Nutraband sells 90% stake in Pocono Pharmaceutical for $5M. 2. Proceeds will support AVERSA Fentanyl's development, targeting $80-$200 million in sales. 3. Shareholders retain 10% stake in new entity Earthvision Bio post-acquisition. 4. Earthvision Bio focuses on sustainable alternatives to traditional products. 5. Nutriband's unique AVERSA technology may enhance opioid safety profiles.
FAQ
Why Bullish?
The sale allows Nutriband to focus resources on a high-potential product. Recent transactions show that focusing on niche breakthroughs can lead to significant market interest and stock price appreciation, similar to shifts seen in other pharmaceutical companies around new product innovations.
How important is it?
The strategic financial maneuver aligns with Nutriband’s focus on innovative products, enhancing growth potential. Investors often react favorably to such optimizations, indicating a favorable outlook on stock performance.
Why Long Term?
While the immediate sale brings cash, the real impact will manifest as AVERSA gains regulatory approval and market traction. Historical trends demonstrate that initial funding rounds have led to significant R&D progress, often resulting in long-term increases in stock valuation.
Nutriband Inc. Announces Agreement to Sell Majority Stake in Pocono Pharmaceutical
ORLANDO, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ: NTRB) has signed a significant agreement to sell a 90% stake in its subsidiary, Pocono Pharmaceutical, for $5 million USD to EarthVision Bio. This transaction marks a pivotal moment for Nutriband as it aims to leverage the proceeds to further its innovative pharmaceutical developments.
Details of the Transaction
The transaction, which is expected to close on December 31, 2025, allows Nutriband shareholders to retain a 10% ownership in EarthVision Bio post-acquisition. EarthVision Bio is focused on developing sustainable products, a mission spearheaded by reputable figures including Dr. Gordon Moore, the founder of Intel (NASDAQ: INTC), and Dr. Hans Franke, former chairman of Chevron Europe.
- Transaction Value: $5 million USD
- Ownership Retained: 10% by Nutriband shareholders
- Expected Closing Date: December 31, 2025
Utilization of Proceeds for Growth
Nutriband plans to allocate the funds from the sale towards the ongoing development of its flagship product, AVERSA Fentanyl. This innovative patch is designed to be the world’s first abuse-deterrent opioid patch, aiming to reduce the risks associated with misuse and accidental exposure to transdermal fentanyl. The anticipated annual sales for AVERSA Fentanyl could reach between $80 million to $200 million in the U.S. market.
About AVERSA™ Technology
Nutriband's AVERSA™ technology is groundbreaking in its approach to drug delivery, incorporating aversive agents that enhance safety and prevent misuse of transdermal drugs, including opioids. The technology is protected under a comprehensive intellectual property portfolio with patents granted in multiple countries including the United States, Europe, Japan, and more.
About Nutriband Inc.
Nutriband Inc. is dedicated to the development of transdermal pharmaceutical products. The company’s innovative AVERSA™ technology can be utilized across various transdermal patches, focusing on preventing the abuse and misuse of medications with addictive potential.
For more information, visit www.nutriband.com.
Forward-Looking Statements
This announcement contains forward-looking statements that express the company’s beliefs and expectations regarding future performance. Such statements involve risks and uncertainties, and actual results may differ materially from those anticipated. Investors are advised to review the risks outlined in Nutriband's periodic filings with the Securities and Exchange Commission.
Contact Information
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
EarthVision Bio
Contact: Tina Hoefer
Phone: 213-531-9995
Email: Tina@earthvisionbio.com